Literature DB >> 15905667

HIV-1 pol replication capacity predicts disease progression.

Eric S Daar1, Karen L Kesler, Terri Wrin, Christos J Petropoulo, Michael Bates, Alice Lail, Nicholas S Hellmann, Edward Gomperts, Sharyne Donfield.   

Abstract

OBJECTIVE: To determine the influence of pol replication capacity on the natural history of HIV-1 infection.
DESIGN: Pol replication capacity was measured using a recombinant virus single cycle assay on baseline plasma specimens from subjects enrolled in the Hemophilia Growth and Development Study.
SETTING: Children and adolescents with hemophilia and HIV-1 infection were enrolled at multiple sites across the USA into a natural history study. PARTICIPANTS: The Hemophilia Growth and Development Study enrolled 207 HIV-1-infected hemophiliacs between 6 and 19 years of age in 1989 and 1990. Subjects were followed every 6 months through 1997 with pol replication capacity measurements available from 128 of the subjects. MAIN OUTCOME MEASURES: A univariate model defined the relationship between pol replication capacity and HIV-1 RNA and CD4 T-cell number. A random effects model assessed the ability of this measure to predict CD4 T-cell decline over time and a Cox proportional hazards model and Kaplan-Meier analyses defined how it predicts clinical progression.
RESULTS: Pol replication capacity measures correlated with baseline HIV-1 RNA, R = 0.189 (P = 0.03) and CD4 T-cell number, -0.197 (P = 0.03). It also independently predicted CD4 T-cell decline over time and progression to AIDS.
CONCLUSIONS: This study demonstrates that pol replication capacity independently influences the natural history of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905667     DOI: 10.1097/01.aids.0000171400.15619.e1

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

1.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 2.  Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature.

Authors:  Albert M L Anderson; John A Bartlett
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

3.  Changes in simian immunodeficiency virus reverse transcriptase alleles that appear during infection of macaques enhance infectivity and replication in CD4+ T cells.

Authors:  Tasha Biesinger; Monica T Yu Kimata; Jason T Kimata
Journal:  Virology       Date:  2007-09-29       Impact factor: 3.616

Review 4.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

5.  Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.

Authors:  Gail Skowron; John G Spritzler; Jodi Weidler; Gregory K Robbins; Victoria A Johnson; Ellen S Chan; David M Asmuth; Rajesh T Gandhi; Yolanda Lie; Michael Bates; Richard B Pollard
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

6.  HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.

Authors:  Matthew Bidwell Goetz; Robert Leduc; Nicole Wyman; Jay R Kostman; Ann M Labriola; Yolanda Lie; Jodi Weidler; Eoin Coakley; Michael Bates; Roberta Luskin-Hawk
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04-01       Impact factor: 3.731

7.  Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy.

Authors:  Thierry Buclin; Amalio Telenti; Rafael Perera; Chantal Csajka; Hansjakob Furrer; Jeffrey K Aronson; Paul P Glasziou
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

8.  Assessing predicted HIV-1 replicative capacity in a clinical setting.

Authors:  Roger D Kouyos; Viktor von Wyl; Trevor Hinkley; Christos J Petropoulos; Mojgan Haddad; Jeannette M Whitcomb; Jürg Böni; Sabine Yerly; Cristina Cellerai; Thomas Klimkait; Huldrych F Günthard; Sebastian Bonhoeffer
Journal:  PLoS Pathog       Date:  2011-11-03       Impact factor: 6.823

9.  Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

Authors:  Kristof Theys; Koen Deforche; Jurgen Vercauteren; Pieter Libin; David Amc van de Vijver; Jan Albert; Birgitta Asjö; Claudia Balotta; Marie Bruckova; Ricardo J Camacho; Bonaventura Clotet; Suzie Coughlan; Zehava Grossman; Osamah Hamouda; Andrzei Horban; Klaus Korn; Leondios G Kostrikis; Claudia Kücherer; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Elisabeth Puchhammer-Stockl; Chiara Riva; Lidia Ruiz; Kirsi Liitsola; Jean-Claude Schmit; Rob Schuurman; Anders Sönnerborg; Danica Stanekova; Maja Stanojevic; Daniel Struck; Kristel Van Laethem; Annemarie Mj Wensing; Charles Ab Boucher; Anne-Mieke Vandamme
Journal:  Retrovirology       Date:  2012-10-03       Impact factor: 4.602

10.  Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.

Authors:  Keiko Sakai; Takayuki Chikata; Zabrina L Brumme; Chanson J Brumme; Hiroyuki Gatanaga; Hiroyuki Gatanag; Shinichi Oka; Masafumi Takiguchi
Journal:  Retrovirology       Date:  2015-11-19       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.